Cara’s Partnership With Vifor Fresenius Provides Validation For Pruritis Drug Korsuva

A Vifor Fresenius joint venture will market Korsuva for CKD-associated pruritis to Fresenius dialysis centers in Europe, and also will do a co-promotion with Cara in the US that may provide a significant head start for the drug.

business

Cara Therapeutics Inc. got a vote of confidence for its Phase III pruritis candidate Korsuva (CR845/difelikefalin) in a deal that licenses ex-US commercial rights to the drug to Vifor Fresenius Medical Care Renal Pharma Ltd.. The agreement also includes a US co-promotion agreement within Fresenius SE & Co. KGAA dialysis facilities.

Cara hopes to obtain US and European approval for Korsuva, a first-in-class, selective kappa opioid receptor agonist, in the unmet...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.